



April 02, 2009 – News Release

Affectis Pharmaceuticals and Mitsubishi Tanabe Pharma Enter Drug Discovery Collaboration

Munich, Germany - Affectis Pharmaceuticals AG, a biopharmaceutical company developing innovative drugs to treat depression and schizophrenia, today announced the closing of a drug discovery collaboration agreement with Mitsubishi Tanabe Pharma Corporation (MTPC), Osaka, Japan, covering the use of Affectis' behavioural pharmacology expertise and technology.

Under the terms of the agreement, Affectis will receive research fees from MTPC as well as development milestones.

The collaboration applies Affectis' extensive expertise in behavioural pharmacology to assist MTPC in discovering new anti-depressants in an ongoing drug discovery program. The discovery program is based on a novel depression target that Affectis helped validate in a previous collaboration between the two companies.

Dr Herbert Stadler, CEO of Affectis, said: "We are very pleased with MTPC's decision to start a new collaboration with Affectis. This is a strong validation of our behavioural pharmacology capabilities and our Behavioural Interference™ technology platform, in particular in view of MTPC's position as a leading player in the global pharmaceutical industry with strengths in CNS research."

Affectis and MTPC first signed a collaboration agreement covering the Behavioural Interference™ technology in February 2005. Under the terms of the previous agreement, Affectis validated a number of potential novel depression targets.

Contacts for Affectis Pharmaceuticals AG:

Luc St-Onge
Fraunhoferstr. 13
82152 Martinsried, Germany
Tel: +49 (0)89 - 893 2811 100
Fax: +49 (0)89 - 893 2811 111
Email: contact@affectis.com
www.affectis.com

Ines-Regina Buth
akampion
Platz vor dem Neuen Tor 2
10115 Berlin, Germany
Tel: +49 (0)30 2363 2768
Fax: +49 (0)30 2363 2769
ines@akampion.com

Notes to Editors

About Affectis Pharmaceuticals AG:

Affectis is a biopharmaceutical company implementing novel concepts for the treatment of psychiatric disorders and inflammatory diseases. The Company has unique capabilities to discover and develop drugs based on pioneering findings in the field of depression,



schizophrenia, and inflammation. These drugs address the increasing need for more comprehensive and faster-acting antidepressants with fewer side effects. Affectis started operations in 2004 as a spin-off from the renowned Max-Planck-Institute of Psychiatry, a world leader in the field of psychiatric research. A strong team of executives and scientists with long-term industry experience contribute to Affectis' progress. The Company raised its third round of venture financing in October 2006, led by AESCAP Venture. Affectis is based in Munich, Germany.

For more information, please visit our website at: www.affectis.com

About Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Corporation (MTPC) is a research-driven global biopharmaceutical leader based in Japan, specializing in research, development and marketing of globally competitive pharmaceutical products focused on cardiovascular and metabolic disorders, and immune and inflammatory diseases. In particular, MTPC strategically focuses on drug discovery in the field of diabetes including a broad range of clinical states from metabolic risks (obesity/dyslipidemia) to complications (renal dysfunction/dialysis) and stroke including the total range of disease phases such as acute phase, convalescence and maintenance.

MTPC, established through the merger of Tanabe Seiyaku Co., Ltd. and Mitsubishi Pharma Corporation in October 2007, is committed to protecting the health of people around the world and contributing to comfortable lifestyles through creating pharmaceuticals.

For more information, please visit the web site at www.mt-pharma.co.jp